Crism Therapeutics: Board Changes

CRISM Therapeutics

02/04/2026 07:00

RNS Number : 1310Z

CRISM Therapeutics Corporation

02 April 2026

 

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

 

2 April 2026

 

 

CRISM Therapeutics Corporation

('CRISM', 'CRISM Therapeutics' or the 'Company')

Board Changes

CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, announces that Dr Nermeen Varawalla has resigned from the Board of Directors in order to pursue other professional interests.  Nermeen was appointed Non-Executive Chair at the Company's Admission to AIM in May 2024 and, as previously announced, in October 2025 stepped back from her role. 

 

Andrew Webb will continue to act as Executive Chair on an interim basis until a new Chair is identified. Gerry Beaney, Independent Non-Executive Director and Chair of the Audit Committee will chair the Remuneration Committee.

 

Andrew Webb, Interim Exec Chair, said: "The Company wishes to thank Nermeen for her valuable contribution to CRISM since our AIM listing in May 2024 and we wish her well with her future endeavours.  A search for a successor with the requisite skills and experience as CRISM progresses towards its phase 2 clinical trial and future commercialisation is underway. We will update the market as to its progress in due course."  

 

 

-Ends-

 

Enquiries:

 

Company
Nomad and Broker
Financial PR
CRISM Therapeutics Corporation
S.P. Angel Corporate Finance LLP
Burson Buchanan
Andrew Webb, Interim Exec Chair
Chris McConville, CSO
Richard Morrison
Vadim Alexandre
Adam Cowl
Henry Harrison Topham / Jamie Hooper
CRISM@buchanancomms.co.uk
via Burson Buchanan
+44 (0) 20 3470 0470
+44 (0) 20 7466 5000

 

 

About CRISM Therapeutics Corporation

 

CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.

 

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.

 

For more information please visit: https://www.crismtherapeutics.com/

 

The Company's LEI is 213800XFW6MKVCHHPW88.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
BOASSMFIFEMSEEL